1. Home
  2. MRAM vs CHRS Comparison

MRAM vs CHRS Comparison

Compare MRAM & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Everspin Technologies Inc.

MRAM

Everspin Technologies Inc.

HOLD

Current Price

$9.41

Market Cap

258.7M

Sector

Technology

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.60

Market Cap

291.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRAM
CHRS
Founded
2008
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
258.7M
291.5M
IPO Year
2016
2014

Fundamental Metrics

Financial Performance
Metric
MRAM
CHRS
Price
$9.41
$1.60
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$14.00
$5.51
AVG Volume (30 Days)
433.4K
1.3M
Earning Date
03-04-2026
03-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
472.00
EPS
N/A
1.43
Revenue
$49,417,000.00
N/A
Revenue This Year
$10.87
$88.67
Revenue Next Year
$8.33
$28.64
P/E Ratio
N/A
$1.11
Revenue Growth
37.51
N/A
52 Week Low
$4.34
$0.72
52 Week High
$17.24
$2.62

Technical Indicators

Market Signals
Indicator
MRAM
CHRS
Relative Strength Index (RSI) 42.11 41.96
Support Level $8.42 $1.55
Resistance Level $9.74 $1.75
Average True Range (ATR) 0.58 0.11
MACD 0.00 -0.01
Stochastic Oscillator 28.25 14.11

Price Performance

Historical Comparison
MRAM
CHRS

About MRAM Everspin Technologies Inc.

Everspin Technologies Inc is a provider of Magnetoresistive Random Access Memory (MRAM) products. Its portfolio of MRAM technologies, including Toggle MRAM and Spin-transfer Torque MRAM (STT-MRAM), delivers superior performance, persistence, and reliability in non-volatile memories that transform how mission-critical data is protected against power loss. The company derives revenue from the sale of MRAM-based products in discrete unit form, licenses of and royalties on MRAM and magnetic sensor technology, the sale of backend foundry services, and design services to third parties. It recognizes revenue in three primary geographic regions; North America; Europe, the Middle East, and Africa (EMEA) and Asia-Pacific (APAC).

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Share on Social Networks: